Risultati della ricerca - Pascual, Tomas

Intrinsic molecular subtypes of HER2+ breast cancer di Prat, Aleix, Pascual, Tomás, Adamo, Barbara

Testo Testo Testo

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer di Griguolo, Gaia, Pascual, Tomás, Dieci, Maria Vittoria, Guarneri, Valentina, Prat, Aleix

Testo Testo Testo

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance di Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel

Testo Testo Testo

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases di Laimito, Katerin Rojas, Gámez-Pozo, Angelo, Sepúlveda, Juan, Manso, Luis, López-Vacas, Rocío, Pascual, Tomás, Fresno Vara, Juan A, Ciruelos, Eva

Testo Testo Testo

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement di Colomer, Ramon, Saura, Cristina, Sánchez‐Rovira, Pedro, Pascual, Tomás, Rubio, Isabel T., Burgués, Octavio, Marcos, Lourdes, Rodríguez, César A., Martín, Miguel, Lluch, Ana

Testo Testo Testo

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer di Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva

Testo Testo Testo

Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2 di Prat, Aleix, Brase, Jan Christoph, Cheng, Yuan, Nuciforo, Paolo, Paré, Laia, Pascual, Tomás, Martínez, Débora, Galván, Patricia, Vidal, Maria, Adamo, Barbara, Hortobagyi, Gabriel N., Baselga, José, Ciruelos, Eva

Testo Testo Testo

Frequency and spectrum of PIK3CA somatic mutations in breast cancer di Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

Testo Testo Testo

A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line... di Ciruelos, Eva, Apellániz‐Ruiz, María, Cantos, Blanca, Martinez‐Jáñez, Noelia, Bueno‐Muiño, Coralia, Echarri, Maria‐Jose, Enrech, Santos, Guerra, Juan‐Antonio, Manso, Luis, Pascual, Tomas, Dominguez, Cristina, Gonzalo, Juan‐Francisco, Sanz, Juan‐Luis, Rodriguez‐Antona, Cristina, Sepúlveda, Juan‐Manuel

Testo Testo Testo

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial di Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

Testo Testo Testo

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial di Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier

Testo Testo Testo

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt... di Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix

Testo Testo Testo

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study di Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodón, Jordi, Burgués, Octavio, Nuciforo, Paolo, Canes, Jordi, Paré, Laia, Dueñas, Marta, Vidal, Maria, Cejalvo, Juan Miguel, Perelló, Antonia, Llommbard-Cussac, Antonio, Dorca, Joan, Montaño, Alvaro, Pascual, Tomás, Oliveira, Mafalda, Ribas, Gloria, Rapado, Inmaculada, Prat, Aleix, Ciruelos, Eva

Testo Testo Testo

Gene expression profiles of breast cancer metastasis according to organ site di Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

Testo Testo Testo

Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy di Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, M. Vittoria, Pernas, Sonia, Gavila, Joaquin, Guarnieri, Valentina, Cortes, Javier, Villagrasa, Patricia, Chic, Núria, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galvan, Patricia, Carey, Lisa A., Perou, Charles M., Prat, Aleix

Testo Testo Testo

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy di Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

Testo Testo Testo

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer di Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix

Testo Testo Testo

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy di Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., Prat, Aleix

Testo Testo Testo

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Stand... di Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio

Testo Testo Testo

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade di Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

Testo Testo Testo